Prime Medicine Management
Management criteria checks 2/4
Prime Medicine's CEO is Allan Reine, appointed in May 2025, has a tenure of less than a year. total yearly compensation is $4.62M, comprised of 10.4% salary and 89.6% bonuses, including company stock and options. directly owns 0.095% of the company’s shares, worth $640.03K. The average tenure of the management team and the board of directors is 0.4 years and 3.4 years respectively.
Key information
Allan Reine
Chief executive officer
US$4.6m
Total compensation
| CEO salary percentage | 10.37% |
| CEO tenure | less than a year |
| CEO ownership | 0.1% |
| Management average tenure | less than a year |
| Board average tenure | 3.4yrs |
Recent management updates
Recent updates
Prime Medicine: Pressing Forward With Lead Liver Targeting Indications
Jul 07Prime Medicine: Initiating Coverage At Hold With 2025 Binary Catalyst For PM359
Apr 25Prime Medicine: Gene Editing Company, Risky Investment
Feb 05Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?
Dec 19
Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies
Nov 26Prime Medicine's Promising Pipeline: PM359 And Cash Burn Concerns
Sep 04Here's Why We're A Bit Worried About Prime Medicine's (NASDAQ:PRME) Cash Burn Situation
Sep 04Prime Medicine Stock: Only For The Most Patient Of Investors
Jun 20Is Prime Medicine (NASDAQ:PRME) In A Good Position To Invest In Growth?
May 14Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene Editing
Jan 28Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?
Aug 25We're Not Very Worried About Prime Medicine's (NASDAQ:PRME) Cash Burn Rate
May 12Will Prime Medicine (NASDAQ:PRME) Spend Its Cash Wisely?
Jan 24CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | -US$199m |
| Mar 31 2025 | n/a | n/a | -US$202m |
| Dec 31 2024 | US$5m | US$479k | -US$196m |
Compensation vs Market: Allan's total compensation ($USD4.62M) is about average for companies of similar size in the US market ($USD3.64M).
Compensation vs Earnings: Insufficient data to compare Allan's compensation with company performance.
CEO
Allan Reine (50 yo)
Dr. Allan Reine, M.D., had been Chief Financial Officer of Prime Medicine, Inc. since January 17, 2024 until May 2025 and its Chief Executive Officer and Director since May 19, 2025. Dr. Reine is a seasone...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chair | 2.3yrs | US$1.82m | 0.32% $ 2.1m | |
| CEO & Director | less than a year | US$4.62m | 0.095% $ 640.0k | |
| Consultant | less than a year | US$2.25m | 3.33% $ 22.3m | |
| Co-Founder | no data | no data | no data | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | 15.44% $ 103.6m | |
| Chief Technical Officer | 3.9yrs | US$2.26m | 0.076% $ 512.0k | |
| Chief Legal Officer | less than a year | no data | no data | |
| Chief Human Resources Officer | 3.2yrs | no data | no data | |
| Senior VP & Head of Clinical | no data | no data | no data |
Experienced Management: PRME's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chair | 2.3yrs | US$1.82m | 0.32% $ 2.1m | |
| CEO & Director | less than a year | US$4.62m | 0.095% $ 640.0k | |
| Co-Founder & Member of Scientific Advisory Board | 3.1yrs | no data | 15.44% $ 103.6m | |
| Independent Director | 5yrs | US$287.59k | 0.012% $ 82.4k | |
| Independent Director | 3.8yrs | US$298.78k | 0.079% $ 530.3k | |
| Independent Director | 3.8yrs | US$294.53k | 0.079% $ 530.3k | |
| Independent Director | 6yrs | US$297.59k | 0.064% $ 430.4k | |
| Member of Scientific Advisory Board | 3.1yrs | no data | no data | |
| Independent Director | 3.8yrs | US$294.72k | 0.079% $ 530.3k | |
| Member of Scientific Advisory Board | 3.1yrs | no data | no data | |
| Independent Director | 3.8yrs | US$294.72k | 0% $ 0 | |
| Member of Scientific Advisory Board | 3.1yrs | no data | no data |
Experienced Board: PRME's board of directors are considered experienced (3.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/29 16:08 |
| End of Day Share Price | 2025/09/26 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Prime Medicine, Inc. is covered by 17 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Konstantinos Biliouris | BMO Capital Markets Equity Research |
| Yevgeniya Livshits | Chardan Capital Markets, LLC |
| Samantha Lynn Semenkow | Citigroup Inc |